The research, led by Huimin Liu, Yan Zhu, Wenting Chen, Shilian Li and colleagues working across the Third Affiliated Hospital of Chongqing Medical University, Southwest Hospital of the Army Medical University and the Chongqing Key Laboratory for Research of Viral Infectious Diseases, took advantage of a clinically diverse patient cohort in a region where hepatitis B virus infection remains a dominant cause of liver disease. In total, 80 patients with chronic liver disease were prospectively recruited: 53 with hepatitis B virus infection, 7 with alcohol-associated liver disease, 6 with drug-induced liver injury, and 14 with liver disease arising from other or unknown causes. Forty demographically matched healthy individuals served as controls, giving the team a reference baseline against which disease-associated changes could be measured.

What distinguishes this investigation from many prior microbiome surveys is its dual-omics design combined with sampling at two sites along the intestinal tract. Fecal samples were collected from all enrolled participants and subjected to metagenomic sequencing, a technique that reads the collective genetic material of the gut microbial community and allows researchers to identify not only which microbes are present but also which functional genes and metabolic pathways they encode. In parallel, the team performed non-targeted metabolomic profiling on the same fecal specimens, capturing the small-molecule chemical landscape produced by the joint activity of microbes and host metabolism. Crucially, in a 25-patient subset, the investigators also obtained small intestinal mucosal biopsies, which were likewise sequenced metagenomically, offering a rare glimpse of the microbial ecology of the upper intestine, the segment of the gut most directly connected to the liver through the portal circulation.

This anatomical dimension matters because of the gut-liver axis, the bidirectional communication system linking the intestine and the liver. Nutrients, microbial products and bacterial metabolites absorbed from the intestine travel directly to the liver through the portal vein, and the liver in turn shapes the intestinal environment through bile acid secretion and immune factors. When the liver is chronically injured, bile acid metabolism and gut motility are often disrupted, which can promote bacterial overgrowth in the small intestine and increase the translocation of microbial products into the portal circulation, fueling inflammation and further liver damage. By sampling both feces and small intestinal mucosa, the study was able to map microbial features at multiple points along this axis rather than relying solely on stool as a proxy.

The exploratory analyses suggested that the different etiologies of chronic liver disease are associated with potentially distinct microbiome and metabolome profiles. The alcohol-associated liver disease group stood out in particular, showing differences in microbial composition and in predicted functional pathways compared with the other groups. This observation is biologically plausible: alcohol and its metabolites directly alter the intestinal environment, disrupt tight junctions between epithelial cells, and select for microbial communities capable of metabolizing ethanol and producing endotoxins. However, the authors are careful to emphasize that the alcohol-associated group comprised only seven patients, and the findings for this subgroup should therefore be interpreted cautiously until they are confirmed in larger cohorts.

On the metabolic side, the non-targeted metabolomic analysis identified etiology-associated metabolic features that separated the disease groups within this cohort. Several metabolite panels showed preliminary discriminatory potential, meaning that combinations of small molecules in fecal samples could, in principle, help distinguish patients with different underlying causes of liver disease. Such metabolic signatures are attractive candidates for non-invasive biomarkers because they can be measured in stool or blood without the need for liver biopsy, which remains the invasive gold standard for assessing liver pathology. The researchers also note that trimethylamine N-oxide, a gut microbe-derived metabolite previously implicated in cardiovascular and metabolic disease, belongs to the class of microbial metabolites of interest in liver disease research, illustrating the clinical relevance of this chemical dimension of the gut-liver axis.

Perhaps the most technically ambitious component of the study was the integrated mapping of microbiome and metabolome data. By correlating specific microbial taxa with specific metabolic pathways, the team uncovered associations pointing toward host-microbe interactions along the gut-liver axis. This kind of integration is essential because microbial composition alone does not reveal function: two communities may contain different species yet perform overlapping metabolic roles, or the same species may behave differently depending on its genomic repertoire and environmental context. Linking who is present with what they are doing chemically brings the field closer to understanding mechanisms rather than merely cataloging correlations, and it generates concrete hypotheses about how microbial products might contribute to liver injury or, conversely, how liver dysfunction reshapes the microbial ecosystem.

The authors are explicit about the limitations of their work, and this transparency is an important part of the study’s scientific value. The cohort, while diverse, was modest in size and unbalanced across etiologies, with hepatitis B virus infection dominating the enrollment and the alcohol-associated, drug-induced and other-cause groups represented by only a handful of patients each. As an exploratory study, it identifies candidate microbial and metabolic features rather than definitive biomarkers, and all associations require validation in larger, well-balanced and independent cohorts before any clinical application can be contemplated. The study was conducted in accordance with the Declaration of Helsinki, with ethical approval from the Ethics Committee of the Army Medical University and informed consent from all participants, and the authors declare no competing interests. The work was supported by the National Key Research and Development Program of China and the Chongqing Medical Scientific Research Project.

Even with these caveats, the study arrives at a moment of growing enthusiasm for microbiome-based approaches in hepatology. Researchers worldwide are investigating whether fecal microbial signatures can predict disease progression, whether microbial metabolites mediate complications such as hepatic encephalopathy, and whether interventions ranging from diet and probiotics to fecal microbiota transplantation can modify the course of liver disease. Multi-omics studies of this kind supply the reference maps on which such efforts depend. By simultaneously profiling bacteria, their genes, their chemical products and the upper intestinal mucosa, the Chinese team has generated a rich dataset that other investigators can interrogate, replicate and extend.

The next steps are clear. Larger cohorts with balanced representation of viral, alcoholic, drug-induced and metabolic liver disease will be needed to confirm which microbial taxa and metabolites truly distinguish each etiology, and longitudinal designs will be required to determine whether these signatures precede disease progression or merely accompany it. If validated, etiology-specific microbiome and metabolome panels could eventually complement existing clinical tests, helping physicians identify the cause of liver injury more rapidly, stratify patients for targeted therapies, and monitor responses to treatment through simple, non-invasive sampling. For now, this study stands as a carefully executed exploratory milestone, demonstrating that the chemical and biological conversation between gut and liver carries etiology-specific information that modern sequencing and metabolomic technologies are finally able to read.

Subject of Research: Gut microbiome and metabolome profiles across diverse etiologies of chronic liver disease

Article Title: Gut microbiome and metabolome profiles in diverse etiologies of chronic liver disease

Article References: Gut microbiome and metabolome profiles in diverse etiologies of chronic liver disease. (n.d.). https://doi.org/10.1186/s13099-026-00877-7

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00877-7

Keywords: chronic liver disease, gut microbiome, metabolome, metagenomics, gut-liver axis, hepatitis B virus, alcohol-associated liver disease, drug-induced liver injury, metabolomics, biomarkers, small intestine, multi-omics

The study was designed to address a glaring gap in the microplastics literature. Although microplastics have been confirmed in human tissues, including the liver, intestines, and even the placenta, most toxicological investigations have relied on in vitro cell cultures or single-sex animal cohorts, leaving regulators with limited information about how whole organisms respond to realistic, repeated exposure. The Health Canada team chose C57BL/6 mice, one of the most thoroughly characterized laboratory strains, and divided animals by sex to capture biological variation that shorter or single-sex studies routinely miss. Crucially, they also compared two particle geometries: uniform commercial spheres, which dominate the literature because they are easy to characterize, and milled particles with jagged, irregular edges, which more closely resemble the fragmented plastics found in food, water, and air.

Animals received the particles by daily oral gavage for 28 consecutive days, a duration that in regulatory toxicology is classified as a subacute exposure window, long enough for effects to emerge in rapidly dividing tissues such as the gut lining, but short enough to isolate direct toxicity from age-related changes. The researchers then assembled an unusually comprehensive assessment battery. They tracked food consumption and body weight throughout the exposure, weighed organs at necropsy, ran complete hematology panels, measured a broad suite of clinical biochemistry markers reflecting liver and kidney function, profiled both innate and adaptive immune cell populations by flow cytometry, quantified pro-inflammatory cytokines, and examined tissues histologically under the microscope. Raman spectroscopy was used to hunt for plastic particles in collected tissues, confirming whether the material actually crossed from the gut lumen into the body.

The first surprise was how quiet the systemic picture looked. Across all treatment groups, there were no significant changes in food consumption, body weight, or relative organ weights. Hematological parameters, including red and white blood cell counts, remained within normal ranges, and clinical biochemistry markers of organ function showed no statistically meaningful disturbances. For anyone who has followed alarmist headlines about microplastics, the results might seem anticlimactic. But the team emphasizes that the absence of classical systemic toxicity endpoints does not mean the exposure was biologically inert. Subtle changes were quietly accumulating in tissues that routine blood panels cannot see, and those changes were distributed unevenly between the sexes.

The most dramatic finding emerged in the gallbladder. Histological examination revealed gallbladder inflammation in 9 of 23 male mice exposed to the particles, compared with only 2 of 24 exposed females, a skew so pronounced that it is unlikely to be chance. The inflammatory lesions appeared in animals exposed to both spherical and milled particles, suggesting that particle chemistry rather than precise geometry drove the response in this organ. The gallbladder is not a tissue that has featured prominently in microplastics research, which has focused overwhelmingly on the intestine, liver, and lungs, and the finding raises immediate questions about biliary health in chronically exposed animals and, by extension, humans. Whether the inflammation reflects direct physical contact by particles transiting the biliary tract, a secondary response to altered bile composition, or an immune-mediated process remains unresolved.

Male mice also showed a second, subtler immune signature: pro-inflammatory cytokines were decreased across all polystyrene-exposed male groups. A drop in inflammatory signaling molecules might superficially sound beneficial, but in immunology, dampened cytokine output can indicate immune dysregulation, a blunting of the normal responsiveness that animals need to fight infections and clear damaged tissue. The adaptive and innate immune cell populations measured by flow cytometry showed no major shifts, which makes the cytokine suppression even more intriguing, because it suggests a functional change in cell behavior rather than a change in cell numbers. The authors note that this pattern was specific to males; females did not display the same systemic cytokine profile.

Female mice told a completely different story, one written in the tissue of the small intestine. Instead of gallbladder inflammation, exposed females developed mild pathological changes in the intestinal lining, most notably alterations in the goblet cell population and in mucus production. Goblet cells are the gut’s dedicated mucus factories, secreting the protective gel layer that lubricates the intestinal surface and forms a critical barrier against bacteria, dietary antigens, and foreign particles. Changes in goblet cell abundance or mucus output are therefore not cosmetic; they can alter gut permeability, shift the microbiome, and modulate how the intestine tolerates everything from food proteins to pathogens. Because the intestine is the first point of contact for ingested microplastics, these findings suggest that in females, the primary biological conversation between plastic and body happens at the gut barrier itself.

Raman analysis added a crucial piece of evidence: polystyrene was detected in both the liver and the intestines of animals of both sexes. This confirms that at least a fraction of the ingested particles crossed or associated with the intestinal epithelium and reached the liver, the body’s central detoxification organ. Particle translocation is a key variable in the risk assessment of nano- and microplastics, because systemic distribution opens the door to effects far beyond the gut. The detection of plastic in liver tissue after only 28 days of exposure demonstrates that the mammalian body does not simply pass these materials through as inert cargo.

Just as important as the sex differences was what did not differ: spherical and milled particles produced broadly similar toxicological results. This is a consequential observation for the field, because much of the existing microplastics literature relies on idealized spheres for experimental convenience. If milled, irregular fragments, which better approximate environmental weathered plastic, behave like spheres in vivo, then laboratory findings using spherical particles may be more transferable to real-world risk than critics have assumed. At the same time, the authors are careful to frame the geometry question as far from settled, and the gallbladder findings appeared across both particle types in this study.

The broader takeaway is a call for sex as a standard variable in microplastics toxicology. Regulatory toxicity testing has only in recent decades moved toward requiring both sexes in study design, and the microplastics field, much of it built on expedient single-sex models, has lagged behind. The Health Canada results demonstrate that pooling or ignoring sex can mask biologically meaningful signals, from suppressed cytokine responses in males to gut barrier remodeling in females. The study was funded by the Government of Canada’s Advancing a Circular Plastics Economy Initiative, reflecting a policy landscape in which plastic production continues to accelerate globally while the health consequences of chronic, low-level human exposure remain only partially mapped. As humans continue to ingest and inhale plastic particles daily, research of this kind provides the granular, sex-disaggregated, mechanism-oriented data that will ultimately determine whether microplastics represent a quiet hazard, an active threat, or something in between.

Subject of Research: Sex-specific toxicological effects of oral polystyrene nano- and microplastic exposure in mice

Article Title: Sex-specific toxicological observations following 28-day oral gavage exposure to spherical and milled polystyrene nano- and microplastic particles in mice

Article References: Sex-specific toxicological observations following 28-day oral gavage exposure to spherical and milled polystyrene nano- and microplastic particles in mice. (n.d.). https://doi.org/10.1186/s43591-026-00226-0

Image Credits: AI Generated

DOI: 10.1186/s43591-026-00226-0

Keywords: microplastics, nanoplastics, polystyrene, toxicology, mice, sex differences, gallbladder inflammation, small intestine, goblet cells, cytokines, oral gavage, Health Canada